Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GE HealthCare Technologies Inc. (GEHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: GEHC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $87.35
1 Year Target Price $87.35
| 12 | Strong Buy |
| 4 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.88% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 33.92B USD | Price to earnings Ratio 15.56 | 1Y Target Price 87.35 |
Price to earnings Ratio 15.56 | 1Y Target Price 87.35 | ||
Volume (30-day avg) 21 | Beta 1.29 | 52 Weeks Range 57.62 - 94.75 | Updated Date 07/1/2025 |
52 Weeks Range 57.62 - 94.75 | Updated Date 07/1/2025 | ||
Dividends yield (FY) 0.19% | Basic EPS (TTM) 4.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.03% | Operating Margin (TTM) 14.78% |
Management Effectiveness
Return on Assets (TTM) 5.87% | Return on Equity (TTM) 26.44% |
Valuation
Trailing PE 15.56 | Forward PE 18.18 | Enterprise Value 40636384101 | Price to Sales(TTM) 1.71 |
Enterprise Value 40636384101 | Price to Sales(TTM) 1.71 | ||
Enterprise Value to Revenue 2.05 | Enterprise Value to EBITDA 10.67 | Shares Outstanding 457884992 | Shares Floating 456694497 |
Shares Outstanding 457884992 | Shares Floating 456694497 | ||
Percent Insiders 0.28 | Percent Institutions 80.69 |
Analyst Ratings
Rating 4 | Target Price 87.35 | Buy 4 | Strong Buy 12 |
Buy 4 | Strong Buy 12 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GE HealthCare Technologies Inc.
Company Overview
History and Background
GE HealthCare Technologies Inc. was founded in 2023 as a spin-off from General Electric. It leverages GE's long history in medical imaging and healthcare technology. It provides services, products, and technologies that support healthcare for the benefit of patients and customers.
Core Business Areas
- Imaging: Develops and manufactures a range of imaging technologies, including MRI, CT, X-ray, and molecular imaging systems.
- Ultrasound: Provides ultrasound systems for various clinical applications, including radiology, cardiology, and obstetrics/gynecology.
- Patient Care Solutions: Offers patient monitoring systems, diagnostic cardiology, and anesthesia delivery technologies.
- Pharmaceutical Diagnostics: Develops and manufactures contrast media and radiopharmaceuticals used in medical imaging procedures.
Leadership and Structure
Peter Arduini serves as the President and CEO. The company operates with a global structure with regional divisions and centralized functions.
Top Products and Market Share
Key Offerings
- MRI Systems: GE HealthCare is a leading provider of MRI systems. It has significant market share in the MRI segment (estimated around 30%). Key competitors include Siemens Healthineers and Philips. Annual revenue estimated to be around $4.5 billion.
- CT Scanners: GE HealthCare's CT scanners are widely used in hospitals and imaging centers. GE is a major market share leader in CT scanners (estimated around 25%). Key competitors are Siemens Healthineers and Canon Medical Systems. Annual revenue estimated to be around $3.5 billion.
- Ultrasound Machines: GE HealthCare has a significant position in the ultrasound market with a comprehensive portfolio of systems. It has a leading market share in ultrasound (estimated around 20%). Competitors are Philips and Siemens Healthineers. Annual revenue estimated to be around $3 billion.
- Contrast Media: GE HealthCare is a leading provider of contrast media for X-ray, CT and MRI. Key competitors are Guerbet and Bracco. Annual revenue estimated to be around $2 billion.
Market Dynamics
Industry Overview
The medical technology industry is experiencing growth driven by aging populations, increasing chronic diseases, and technological advancements. Demand for medical imaging, diagnostics, and patient monitoring is rising.
Positioning
GE HealthCare is a well-established player with a broad portfolio, global presence, and strong brand recognition. Its competitive advantages include its installed base, technological expertise, and service capabilities.
Total Addressable Market (TAM)
The global medical device market is expected to reach over $600 billion by 2030. GE HealthCare is positioned to capture a significant share of this market through innovation and expansion in high-growth areas.
Upturn SWOT Analysis
Strengths
- Strong Brand Recognition
- Extensive Product Portfolio
- Global Presence
- Established Distribution Network
- Innovation in Medical Technology
Weaknesses
- Dependence on Healthcare Spending
- Exposure to Regulatory Changes
- Impact from Supply Chain Disruptions
- Intense Competition
Opportunities
- Expansion in Emerging Markets
- Development of New Technologies (AI, Digital Health)
- Partnerships and Acquisitions
- Increasing Demand for Personalized Medicine
Threats
- Pricing Pressures
- Technological Disruption
- Economic Downturns
- Changes in Reimbursement Policies
Competitors and Market Share
Key Competitors
- Siemens Healthineers (SIEGY)
- Philips (PHG)
- Canon Medical Systems (Not Publicly Traded in the US)
Competitive Landscape
GE HealthCare benefits from its brand and installed base, but faces competition from Siemens Healthineers and Philips, which have similar scale and scope. Differentiation through innovation and service is crucial.
Major Acquisitions
Caption Health
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: Expanding AI-powered ultrasound capabilities and expanding into the personalized health sector.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is primarily linked to GE's historical performance prior to the spin-off. GE Healthcare is now charting its own organic growth trajectory.
Future Projections: Analyst projections for GE HealthCare's future growth are dependent on market conditions, technological advancements, and strategic execution.
Recent Initiatives: GE HealthCare is investing in digital health solutions, expanding its presence in emerging markets, and developing new products and technologies.
Summary
GE HealthCare is a strong player in the medical technology industry, boasting a broad product portfolio and global reach. It leverages its established brand and focuses on innovation. Challenges include managing intense competition and adapting to changing healthcare regulations. Overall, GE Healthcare's strategic focus on digital transformation and expansion into emerging markets will ensure a successful and promising future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
- Press Releases
- Company Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Real-time access to financial data would be required for a definitive accurate analysis. Do your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GE HealthCare Technologies Inc.
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2023-01-04 | President, CEO & Director Mr. Peter J. Arduini | ||
Sector Healthcare | Industry Health Information Services | Full time employees 53000 | Website https://www.gehealthcare.com |
Full time employees 53000 | Website https://www.gehealthcare.com | ||
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.